Objective: To study the relationship between thinprep cytologic test and the types of human papilloma virus (HPV) infection in cervical precancerous lesion screening.
Methods: To perform high-risk HPV types test in 1375 samples. Choose 256 positive samples to take thinprep cytologic test (TCT) and directed biopsies under colposcopy. Adopting two-channels real time PCR to genotype and quantify eight high risk HPV DNA (high risk types: HPV 16, 18, 45, 31; intermediate risk types: HPV 33, 52, 58, 67).
Results: There are 256 positive samples in High risk HPV DNA test (18.62%). WNL rate for TCT is 16.41% (42/256), ASCUS and above rate for TCT is 83.59% (214/256). There is no statistically significant difference in the viral loads of HPV infection rate between the TCT negative patients and positive patients (P > 0.5). Positive correspondence rate for TCT and biopsy are 92.86% (39/42), 81.36% (48/59), 85.19% (23/27) and 9/10.
Conclusion: High-risk HPV types checking combined with TCT and biopsy can raise positive rate significantly. It should be used as a reliable method for early diagnosis in cervical cancer and CIN screening.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Donor Type Does Not Impact Late Graft Failure Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Based Graft-Versus-Host Disease Prophylaxis.
Transplant Cell Ther
January 2025
Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, MA. Electronic address:
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been reported to be as high as 12-20% in haplo-HCT recipients using PTCy. The objective of this study was to determine if donor type influenced the risk of late graft failure following RIC HCT using PTCy-based GVHD prophylaxis.
View Article and Find Full Text PDFOutcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older: A Systematic Review and Meta-analysis.
Transplant Cell Ther
January 2025
University of Kansas Medical Center, Kansas City, KS.
Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a potential cure for many hematological malignancies. Historically, older adults were not considered eligible for allo-HCT due to increased toxicity and mortality concerns. This systematic review and meta-analysis aim to explore the outcomes of allo-HCT in patients aged 70 years or older.
View Article and Find Full Text PDFDetecting epithelial-mesenchymal transition signaling molecules in cervical epithelial cells aids in the early diagnosis of cervical lesions.
BMC Cancer
December 2024
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Background: This study aimed to investigate the potential utility of Epithelial-mesenchymal transition (EMT) signaling cell detection in the early diagnosis of cervical lesions.
Methods: Enrichment of cervical epithelial cells was carried out using a calibrated membrane with 8-μm diameter pores. RNA-in situ hybridization (RNA-ISH) was employed to detect and characterize EMT cells utilizing specific EMT markers.
Clinical Outcomes of Early WT1 mRNA Reduction After Remission Induction in Newly Diagnosed Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
December 2024
Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Wilms' Tumor 1 (WT1) mRNA is a non-specific marker of measurable residual disease in acute myeloid leukemia (AML). Few studies have focused on the prognostic value of WT1 mRNA after initial remission induction of patients with AML who have received transplant treatments. Thus, we retrospectively analyzed the clinical features and prognostic impact of WT1 mRNA reduction in patients with AML after initial remission induction at our hospital.
View Article and Find Full Text PDFClinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study.
PLoS One
December 2024
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Aim: To investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
Methods: Between 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
Results: 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!